Systemic Cancer Therapy‐Related Adverse Drug Reactions and Associated Clinical Outcomes Among Lymphoma Patients at Kenyatta National Hospital
Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/jcpt/1766313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 18.06.2026. Verfasst von Ivy Kerubo Mochere und 1 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Combination chemotherapy regimens are the mainstay of treatment for Hodgkin lymphoma (HL) and non‐Hodgkin lymphoma (NHL). Their narrow therapeutic indices often result in adverse drug reactions (ADRs) that can interrupt therapy, increase resource utilization, and worsen patient outcomes. Data on the burden and characteristics of systemic cancer therapy‐related ADRs among lymphoma patients in Kenya are scarce. Hence, this study aimed to assess the prevalence, types, severity, preventability, and clinical outcomes of systemic cancer therapy‐related ADRs among adult HL and NHL patients treated at Kenyatta National Hospital (KNH).
Methods
This retrospective cohort study involved 100 adult patients (≥ 18 years) diagnosed with HL or NHL who received systemic cancer therapy at KNH between January 2020 and December 2024. Data were extracted using a structured abstraction tool and included patient demographics, lymphoma subtype, systemic cancer therapy, ADR types, severity, preventability, and associated clinical outcomes. Statistical analysis was conducted using SPSS Version 29.0.01 software.
Results
Systemic cancer therapy‐related ADRs occurred in 98% of patients, demonstrating a very high burden in this population. The most frequently observed ADRs were anemia (31%), followed by nausea/vomiting (24%) and neutropenia (14%). Most ADRs were mild (51%) or moderate (33%), though 14% were classified as severe. Preventability analysis showed that 57% of ADRs were definitely preventable and 27% probably preventable. Clinical consequences included treatment interruptions (47%), hospital admissions (19%), and ADR‐related mortality in 8% of patients.
Conclusion
The prevalence of systemic cancer therapy‐related ADRs among lymphoma patients at KNH is extremely high. While many reactions are not severe, most are preventable, indicating gaps in monitoring and regimen optimization. Strengthening pharmacovigilance, early toxicity detection, and individualized regimen selection could help reduce toxicities and improve outcomes for lymphoma patients in Kenya.
Zitieren
APA
Mochere, I. K., & Degu, A. (2026). Systemic Cancer Therapy‐Related Adverse Drug Reactions and Associated Clinical Outcomes Among Lymphoma Patients at Kenyatta National Hospital. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/1766313
Vancouver
Mochere IK, Degu A. Systemic Cancer Therapy‐Related Adverse Drug Reactions and Associated Clinical Outcomes Among Lymphoma Patients at Kenyatta National Hospital. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/1766313
BibTeX
@article{Mochere2026,
author = {Mochere, Ivy Kerubo and Degu, Amsalu},
title = {Systemic Cancer Therapy‐Related Adverse Drug Reactions and Associated Clinical Outcomes Among Lymphoma Patients at Kenyatta National Hospital},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jcpt/1766313}
}
EUVIMED